Jazz Pharmaceuticals plc
JAZZ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.5B
Close$
$593.56
145.7% upside
Current Fair Value
145.7% upsideUndervalued by 145.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $15.50 Billion |
|---|---|
| Enterprise Value | $19.17 Billion |
| Earnings per Share | $-5.84 |
| Beta | 0.32 |
| Outstanding Shares | 64,700,000 |
Return
| Return on Equity | 4.91% |
|---|---|
| Return on Assets | 1.72% |
| Return on Invested Capital | 3.19% |
Valuation & Multiples
| P/E Ratio | 67.47 |
|---|---|
| PEG | -23.09 |
| Price to Sales | 3.35 |
| Price to Book Ratio | 3.77 |
| Enterprise Value to Revenue | 4.06 |
| Enterprise Value to EBIT | 63.45 |
| Enterprise Value to Net Income | 93 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 1.36 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$6.26
Consensus analyst estimateRevenue Estimate
$1.21 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 23, 2027
EPS Estimate
$6.97
Consensus analyst estimateRevenue Estimate
$1.28 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 106.98% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 4,700▼ 97.71% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.71%▼ 85.03% |
|---|---|
| Total Invested | $2.88B▼ 81.52% |
| Investors Holding | 332▼ 334.00% |
About Jazz Pharmaceuticals plc
1,210 employees
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...